

Press release

PPRS Group announces the acquisition of The Siesta Group, a service provider for clinical trials, expert in the measurements of brain activity and sleep.

Vienna, February 20th

PPRS Group has acquired a majority stake of The Siesta Group from two Austrian venture capital funds, GXT and Fundula. The management team, led by Véronique M. Martineau since 2014, and the scientific founders of the company, remain as minority shareholders and will actively participate in the group's future direction and success.

Burkhard Feurstein, CEO of GXT, commented that: *"The Siesta team has done a marvelous job in the past and can now create even more value for its customers and shareholders within a global Biotech & Medtech Powerhouse like PPRS Group."*

Véronique M. Martineau added: *"By joining PPRS, our company will reinforce its position as a key-player in the clinical research space by providing robust, innovative and strong value-added solutions for the measurements of sleep, wakefulness and brain activity, with secure and regulatory compliant exchange tools, to facilitate biomarker analysis and improve predictive capabilities."*

Fabrice Arousseau, CEO of PPRS Group, expressed his delight to see the two teams brought together and explained that: *"This partnership perfectly fits with our global strategy aiming to be at the forefront of drug and medical device development in neuroscience."*

About Siesta:

Following the EU research project SIESTA, coordinated by the Austrian Research Institute for Artificial Intelligence (OFAI), The Siesta Group was founded in 2002 by recognized experts in the vigilance and sleep fields: Dr. Peter Anderer, Dr. Georg Dorffner, Dr. Michael Grözinger, Dr. Dieter Kunz, Dr. Thomas Penzel, Dr. Bernd Saletu.

Over the last 15 years, the company has become a world-renowned expert in the analysis of brain activities and sleep, offering its services worldwide with its EEG, PSG and actigraphy solutions. Thanks to its high-quality services in standardization, recording, analysis and reporting of regulatory compliant clinical data, the company offers to pharmaceutical and biotech companies valuable endpoints for CNS-active drug-candidates developments.

About PPRS Group:

Based in Paris & Colmar (France) and Boston (Massachusetts, USA), PPRS is an independent French group that currently develops or supports multiple clinical development projects, including 7 drug-candidates and 5 medical devices. As of today, the company relies on a team composed of 50 dedicated people.

With deep expertise and a broad network in the Central Nervous System field, and a multi-referential quality system, PPRS works with pharmaceutical, biotech and medtech companies of all sizes at each step of their development process. Its experienced multidisciplinary team has participated in more than 700 clinical trials and in the development of more than 150 drug candidates.

By consolidating its unique expertise in predictive drug development, patients' data recording & monitoring devices and AI-based clinical algorithms, PPRS Group is paving the way toward personalized medicine, helping to bring out innovative diagnostic tools, tailored treatments and improved patients' support solutions.

PPRS Group:

Baptiste Planat
bpl@pprs-research.com
00 33 6 07 38 41 23

Press contact:

Maxime Luthringer
communication@pprs-research.com
00 41 79 565 26 58